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ABSTRACT
Therapeutic resistance is a major obstacle to achieving durable clinical responses 
with targeted therapies, highlighting a need to elucidate the underlying mechanisms 
responsible for resistance and identify strategies to overcome this challenge. An 
emerging body of data implicates the tyrosine kinase MET in mediating resistance to 
BRAF inhibitors in BRAFV600E mutant melanoma. In this study we observed a dominant 
role for the HGF/MET axis in mediating resistance to BRAF and MEK inhibitors in 
models of BRAFV600E and NRAS mutant melanoma. In addition, we showed that MAPK 
pathway inhibition induced rapid increases in MET and GAB1 levels, providing novel 
mechanistic insight into how BRAFV600E mutant melanoma is primed for HGF-mediated 
rescue. We also determined that tumor-derived HGF, not systemic HGF, may be 
required to convey resistance to BRAF inhibition in vivo and that resistance could be 
reversed following treatment with AMG 337, a selective MET inhibitor. In summary, 
these findings support the clinical evaluation of MET-directed targeted therapy to 
circumvent resistance to BRAF and MEK inhibitors in BRAFV600E mutant melanoma. In 
addition, the induction of MET following treatment with BRAF and MEK inhibitors has 
the potential to serve as a predictive biomarker for identifying patients best suited 
for MET inhibitor combination therapy.
INTRODUCTION
Approximately half of all malignant melanomas 
harbor an activating mutation in the serine/threonine 
kinase BRAF; ~90% of these mutations involve a valine to 
glutamic acid substitution at residue 600 (V600E) [1]. This 
mutation constitutively activates the mitogen-activated 
protein kinase (MAPK) signaling pathway driving 
proliferation and survival [1–3]. The BRAF inhibitor 
vemurafenib was the first approved targeted therapy  for 
BRAFV600E metastatic melanoma, achieving a response rate 
of 50% to 60% and significantly improving progression-
free survival (PFS) and overall survival (OS) [4, 5]. 
More recently, combination therapy of BRAF and MEK 
inhibitors has improved response rates to approximately 
70% in patients with BRAFV600E mutant melanoma while 
exhibiting evidence of clinical benefit in almost all patients 
[6]. However, nearly all patients that respond to therapies 
targeting the MAPK pathway will ultimately develop 
resistance and undergo disease progression within 6 to 7 
months of initial therapy [5].
There is evidence for a broad spectrum of genomic 
and non-genomic mechanisms of acquired resistance 
to BRAF inhibitors in metastatic melanoma. Genomic 
alterations thought to be responsible for resistance include 
activating mutations in MEK and NRAS, alternative 
splicing and amplification of BRAF, and activation of the 
phosphatidylinositol 3-kinase (PI3K) pathway through 
loss of PTEN or mutations in PIK3CA and AKT [7–12]. 
Methylome and transcriptional analysis of tumors serially 
biopsied prior to therapy with a MAPK pathway inhibitor 
and following clinical relapse suggests recurrent non-
genomic mechanisms, including up-regulation of the 
MET receptor tyrosine kinase (RTK) and down-regulation 
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of β-catenin-LEF1, can also be responsible for acquired 
resistance to these inhibitors [12].
Several studies have demonstrated an emerging role 
for growth factor–mediated signaling in the resistance 
to inhibitors targeting the MAPK pathway. Specifically, 
hepatocyte growth factor (HGF), the cognate ligand for 
the RTK MET, has been shown to convey resistance to 
vemurafenib and a related analog, PLX4720, in BRAF 
mutant melanoma cell lines [13, 14]. This resistance is 
driven by reactivation of the MAPK and PI3K signaling 
pathways. Elevated HGF levels from autocrine (tumor 
cell), paracrine (stromal), or systemic production were 
proposed to represent a novel mechanism of vemurafenib 
resistance. These data, along with the finding that up-
regulation of MET is associated with acquired resistance 
to MAPK pathway inhibitor therapy suggest that 
combined treatment with HGF/MET inhibitors may 
provide additional clinical benefit.
Growth factor–mediated activation of the MAPK 
pathway is regulated by a complex network of extracellular 
signal-regulated kinase (ERK)–dependent negative 
feedback loops, which attenuate signal magnitude and 
duration. For example, MAPK pathway activation can 
lead to the induction of Sprouty proteins, which sequester 
adaptor proteins from their associated RTKs, leading to 
suppression of RAS activation and reduced downstream 
signaling [15, 16]. In oncogene-addicted BRAFV600E 
mutant melanoma, flux through the MAPK pathway is 
high, driving robust ERK-dependent negative feedback. 
Feedback loops targeting RTKs and adaptor proteins would 
be expected to have little to no effect on MAPK pathway 
signaling because of their intervention upstream of activated 
BRAF; however, upon treatment with a BRAF inhibitor 
and subsequent inhibition of MAPK pathway signaling, 
ERK-dependent negative feedback loops are diminished, 
relieving significant suppression of upstream nodes and 
priming cells for growth factor/RTK–driven resistance. 
Similar resistance mechanisms have been reported in triple-
negative breast cancer (TNBC) where inhibition of MAPK 
pathway signaling resulted in the dynamic upregulation 
and activation of select RTKs [17]. Combined treatment 
with a MEK inhibitor and pharmacologic inhibition, or 
small interfering RNA knockdown of the implicated RTKs, 
resulted in synergistic effects on TNBC cell line viability. 
These findings highlight a compensatory role for growth 
factors and their accompanying RTKs in reactivating 
MAPK pathway signaling and conveying resistance to 
downstream targeted therapy.
In this manuscript we report findings that provide 
further insight into the mechanism of HGF-mediated 
rescue of BRAF or MEK inhibition in BRAFV600E mutant 
melanoma and demonstrate that MET and GAB1 (a key 
adaptor protein in HGF/MET signaling) are uniquely 
upregulated following MAPK pathway inhibition. The 
induction of MET and GAB1 primes cells for rescue by 
HGF, via activation of both the MAPK and PI3K signaling 
pathways. In addition, a strong correlation was observed 
between MET induction and strength of HGF rescue, 
suggesting that MET induction may serve as a predictive 
marker for identifying patients most likely to benefit from 
combined BRAF and MET inhibitor therapy. Finally, we 
demonstrate that local/tumor HGF expression may be 
required to convey resistance to BRAF inhibition in vivo, 
observing rescue when HGF is expressed in the tumor 
microenvironment but not when expressed systemically. 
In summary, these findings add significant and novel 
mechanistic insight into the potential role of HGF/MET 
signaling in mediating resistance to BRAF and MEK 
inhibitors and support the clinical evaluation of MET kinase 
inhibitors and HGF-neutralizing antibodies in melanoma.
RESULTS
HGF rescues BRAF and NRAS mutant 
melanoma cell lines from the growth inhibitory 
effects of MAPK pathway inhibition
To assess whether HGF could rescue BRAFV600E 
mutant melanoma cells from BRAF inhibition, three cell 
lines were treated with vemurafenib in the presence or 
absence of HGF. Proliferative capacity was measured with 
live cell imaging by tracking changes in confluency over 
time. In agreement with its documented antiproliferative 
effects [18, 19], vemurafenib treatment resulted in little to 
no increase in confluency over the experimental duration 
(Figure 1A). In contrast, coadministration of HGF with 
vemurafenib resulted in a rapid and profound rescue 
of cell proliferation, achieving growth rates similar to 
those observed with vehicle or HGF treatment alone 
(Figure 1A). Terminal viability analysis identified a 
similar HGF-mediated rescue, with fourfold to ninefold 
improvements in viability over vemurafenib treatment 
alone (Figure 1B).
To determine the prevalence of HGF rescue, 14 
BRAFV600E mutant melanoma cell lines were treated 
with a dose titration matrix of vemurafenib and HGF 
(Supplementary Figure 1A). Compared with vemurafenib 
treatment alone (3 μM), cotreatment with HGF improved 
viability by > 20% in 10 cell lines, >100% in seven 
cell lines, and > 200% in three cell lines (Figure 1C), 
suggesting that HGF may represent a robust and frequent 
resistance mechanism to BRAF inhibitor therapy in 
BRAFV600E mutant melanoma. In cell lines exhibiting 
HGF-mediated rescue, resistance was observed across 
a wide range of vemurafenib concentrations and with as 
little as 4 ng/mL HGF (Figure 1C).
To understand whether rescue was unique to HGF or 
shared by other RTK ligands, six additional growth factors 
(basic fibroblast growth factor [bFGF], epidermal growth 
factor [EGF], insulin-like growth factor 1 and 2 [IGF1 
and IGF2], insulin, and platelet-derived growth factor 
[PDGF]) were tested. HGF was the predominant growth 
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Figure 1: HGF treatment rescues BRAFV600E mutant melanoma cells from the effects of vemurafenib. (A) BRAFV600E 
mutant melanoma cell lines were treated with vehicle, vemurafenib (2 μM), HGF (100 ng/mL), or vemurafenib + HGF. Cells were imaged 
every 3 hours, tracking changes in confluency as a measure of proliferation. *P < 0.01. (B) Bar graphs depict results from terminal viability 
assays (ATP concentration) normalized to vehicle-treated control. Error bars represent SD across replicates (n = 4). **P < 0.001. (C) 
BRAFV600E mutant melanoma cell lines were treated with a serial dilution matrix of vemurafenib (3 μM top dose with five-step 1:3 serial 
dilution) and one of seven growth factors (300 ng/mL top dose with five-step 1:3 serial dilution; top doses of 900 and 1000 ng/mL were 
used for G361 and COLO679, respectively) for 72 hours. Viability was quantified and reported as percentage rescue from vemurafenib 
treatment alone.
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factor capable of rescuing BRAFV600E mutant melanoma 
cell lines from vemurafenib. bFGF was the only additional 
growth factor to exhibited significant rescue; however, the 
magnitude and prevalence was far less than that observed 
with HGF (Figure 1C; Supplementary Figures 1B–1C). 
Having observed significant HGF rescue in the 
initial panel of cell lines, an additional 12 patient-
derived BRAFV600E mutant melanoma cell lines with 
accompanying clinical data (Supplementary Table 1) 
were profiled for HGF rescue. Here we tested the ability 
of HGF to rescue cells from dabrafenib, a selective BRAF 
inhibitor, approved for the treatment of BRAFV600E mutant 
melanoma, with similar clinical efficacy as vemurafenib 
but a differentiated safety profile. Three of 12 cell lines 
were rescued from dabrafenib treatment by > 20% 
(Supplementary Figure 2A), including lines derived from 
patient biopsies obtained before targeted therapy and lines 
derived from biopsies at progression after treatment with 
vemurafenib (Supplementary Table 1).
Because BRAF + MEK inhibitor combination 
therapy is replacing BRAF inhibitor monotherapy and 
emerging as the standard targeted therapy in BRAFV600E 
mutant melanoma, [20–22] we sought to test whether HGF 
could rescue BRAFV600E mutant G361 cells from treatment 
with dabrafenib and trametinib (selective BRAF and 
MEK inhibitors approved for use in combination to treat 
metastatic BRAFV600E mutant melanoma). HGF partially 
rescued G361 cells from combination treatment across a 
wide range of concentrations (Figure 2), suggesting HGF 
may also confer resistance to this therapeutic combination. 
In addition to BRAF mutations, metastatic 
melanoma frequently harbors activating NRAS mutations 
(15%–28%) [23–25] for which MEK inhibitor therapy 
has shown early clinical activity [25, 26]. To characterize 
whether HGF could rescue NRAS mutant melanoma from 
trametinib, six patient-derived NRAS mutant melanoma 
cell lines (Supplementary Table 1) were tested. Four 
lines were rescued by > 20% (Supplementary Figure 2B), 
highlighting the breadth of this rescue mechanism outside 
the BRAFV600E mutant setting.
Inhibition of MET signaling attenuates HGF–
mediated rescue of MAPK pathway inhibition in 
a BRAF mutant melanoma cell Line
MET is the cognate RTK for HGF. To confirm its 
role in mediating HGF rescue, Compound 20, a potent and 
highly selective class I MET inhibitor [27, 28], was used to 
treat G361 cells rescued from vemurafenib or PD0325901, 
a selective MEK inhibitor [29]. Compound 20 addition 
attenuated HGF-mediated rescue of vemurafenib, resulting 
in a growth curve plateau, consistent with MET inhibition 
and restoration of the vemurafenib antiproliferative effect 
(Figure 3A). To further explore the underlying mechanism 
of HGF rescue, we performed cell cycle analysis and 
confirmed that selective MET inhibition could attenuate 
HGF rescue by inducing a G1 growth arrest, as was 
seen with vemurafenib treatment alone (Figure 3B, 
Supplementary Figure 3A). In contrast, Compound 20 
addition to cells rescued from PD0325901 produced 
a growth curve with a negative slope (Figure 3A), 
suggesting that combined MEK + MET inhibition, in the 
context of HGF rescue, induces greater cell-killing effects 
than BRAF + MET inhibition. Subsequent cell cycle 
analysis confirmed these findings, demonstrating that 
MET inhibition prevented HGF rescue from PD0325901 
because of an increase in the percentage of subG1 cells 
and a reduction in proliferating cells (BrdU+; Figure 3B, 
Supplementary Figure 3B). HGF also rescued G361 
cells from higher concentrations of PD0325901 (1 μM; 
Figure 2: HGF treatment rescues a BRAFV600E mutant melanoma cell line from the effects of a BRAF + MEK inhibitor 
combination. G361 cells were treated with a serial dilution matrix of dabrafenib and trametinib ± HGF (25 ng/mL) for 72 hours. Viability 
was quantified (ATP concentration) and reported as raw luminescence (representative results from one of two independent experiments).  
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Supplementary Figure 3C). Here, cell cycle analysis 
revealed robust cell killing (subG1) with PD0325901 
alone; HGF addition rescued a significant portion of 
the subG1 cells, returning them to a proliferative state 
(BrdU+). Again, selective MET inhibition with Compound 
20 reversed HGF-mediated rescue.
To investigate the underlying signaling changes 
responsible for HGF rescue, cell lysates from G361 
(rescued) and A375 (not rescued) cell lines were profiled 
by immunoblot analysis to characterize effects on the 
downstream PI3K and MAPK signaling pathways when 
rescued from BRAF or MEK inhibition. As expected, 
given the presence of activating BRAF mutations, both 
cell lines exhibited robust pMEK and pERK levels, which 
were inhibited by vemurafenib treatment (Figure 3C). 
Cotreatment with HGF rescued a significant portion 
of the pMEK and pERK signals in G361 but not A375 
cells. Furthermore, a similar rescue of pERK, although 
to a lesser extent, was observed in G361 cells upon HGF 
addition to PD0325901. As anticipated, MET inhibition 
with Compound 20 reversed the HGF rescue of MAPK 
pathway signaling, returning pERK and pMEK signals to 
levels seen with BRAF or MEK inhibitor treatment alone. 
HGF treatment also exhibited evidence of PI3K pathway 
activation, as measured by increased pAKT levels in G361 
but not A375 cells (Figure 3C). To confirm the role of PI3K 
pathway signaling in mediating HGF rescue, AMG 511, a 
selective class I PI3K inhibitor [30], was added to G361 
cells rescued from vemurafenib or PD0325901. In both 
cases, PI3K inhibition attenuated the HGF-mediated rescue 
of MAPK pathway inhibition (Supplementary Figure 4). 
These findings demonstrate that HGF rescue from BRAF 
or MEK inhibitor treatment was mediated by both the 
PI3K and MAPK signaling pathways, and selective MET 
inhibition blocked this underlying mechanism. 
MAPK pathway inhibition induces marked 
increases in MET and GAB1 transcript and 
protein levels, priming signaling for HGF rescue
Having characterized the effects of HGF rescue on 
downstream PI3K and MAPK signaling pathways, we next 
investigated the role of MET and GAB1, a key adaptor 
protein in HGF/MET signaling [12, 31], in mediating 
resistance. HGF treatment of G361 cells resulted in a 
limited increase in pMET and pGAB1 levels (Figure 4A). 
In vemurafenib- or PD0325901-treated cells, HGF induced 
far greater increases in the phosphorylation state of these 
two proteins. Immunoblot analysis of total MET revealed 
two bands, both of which were induced following treatment 
with either a BRAF or MEK inhibitor (Figure 4A). The 
higher molecular weight band (~170 kDa) represents the 
MET proreceptor (p170met), which is cleaved to form 
the mature receptor composed of disulfide-linked alpha 
and beta subunits [32]. The lower molecular weight 
band corresponds to the beta subunit (~140 kDa), the 
levels of which were inversely correlated with MAPK 
pathway signaling (pERK) (Figures 3C and 4A), 
suggesting that MAPK pathway inhibition may promote 
proteolytic cleavage of the MET proreceptor to its mature 
alpha and beta subunits. Furthermore, a significant 
increase in total GAB1 expression was similarly observed 
upon treatment with either a BRAF or MEK inhibitor 
(Figure 4A). Taken together these data suggest that the 
increases in total MET and GAB1 may prime BRAF 
mutant melanoma cells for HGF-mediated rescue. As 
expected, cotreatment with Compound 20 significantly 
reduced MET and GAB1 phosphorylation levels. To 
understand whether this induction in total protein 
following MAPK pathway inhibition was unique to 
MET and GAB1, we profiled the same G361 lysates with 
antibodies to a panel of RTKs and adaptor proteins, some 
of which are known targets of MAPK pathway–mediated 
negative feedback loops [33]. Only MET and GAB1 
exhibited significant induction following vemurafenib 
or PD0325901treatment (Figure 4A), indicating this 
induction may contribute to the underlying mechanism 
of HGF rescue and explain the unique ability of HGF 
to rescue BRAF mutant melanoma cells from MAPK 
pathway inhibition. 
Previous reports have documented a network of 
ERK-dependent negative feedback loops that attenuate 
MAPK signaling, some of which regulate signaling at the 
RTK level [15, 33, 34]. In BRAFV600E mutant melanoma, 
where robust MAPK pathway signaling is present, we 
hypothesized that MET and GAB1 levels were repressed 
by an ERK-dependent negative feedback mechanism. Upon 
treatment with a BRAF or MEK inhibitor, ERK-dependent 
feedback would be expected to diminish, resulting in 
elevated MET and GAB1. To further characterize the 
increase in MET and GAB1 after vemurafenib treatment, 
we performed a time course experiment in G361 cells 
(Supplementary Figure 5). Although ERK phosphorylation 
was inhibited within 15 minutes of treatment, increases in 
MET and GAB1 were not observed until 8 hours post-
treatment. This delay suggested changes in transcription 
may be regulating the protein level increases. To test 
this hypothesis, qRT-PCR was used to evaluate changes 
in MET and GAB1 transcript levels. A robust increase in 
MET and GAB1 transcripts following a time course of 
vemurafenib treatment was observed, reaching a maximal 
induction of 3.5-fold and 6-fold, respectively, at 30 hours 
(Figure 4B). Further characterization revealed the increases 
in MET and GAB1 transcripts were unique among a panel 
of tested RTK and adaptor proteins (Figure 4C). The only 
other transcript to exhibit greater than twofold increase 
following vemurafenib treatment was PDGFRA; however, 
no PDGFRA protein was detected in G361 cells in the basal 
or MAPK pathway inhibited state (unpublished data). To 
confirm this observation was not limited to G361 cells, two 
additional HGF-rescuable BRAFV600E mutant melanoma 
cell lines, SK-MEL-5 and COLO679, were characterized 
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Figure 3: MET inhibition attenuates HGF rescue of BRAF and MEK inhibitors in G361 BRAFV600E mutant melanoma 
cells. (A) Cells were treated with vehicle, vemurafenib (2 μM), PD0325901 (200 nM), vemurafenib + HGF (100 ng/mL) or PD0325901 
+ HGF. Compound 20 (100 nM) was added at 94 hours (broken line). Cells were imaged every 4 hours, tracking changes in confluency as 
a measure of proliferation. Bars represent SD across replicate wells (n = 3). *P < 0.01. (B) Cells were treated with vehicle, vemurafenib 
(2 μM), PD0325901 (200 nM), vemurafenib + HGF (100 ng/mL), PD0325901 + HGF, vemurafenib + HGF + Compound 20 (100 nM) or 
PD0325901 + HGF + Compound 20 for 48 hours. BrdU labeling reagent was added for the final 2 hours of treatment. Cells were harvested, 
fixed, permeabilized, stained, and analyzed by flow cytometry. (C) HGF-rescued G361 cells and nonrescued A375 cells were treated with 
vehicle, HGF (100 ng/mL), vemurafenib (2 μM), PD0325901 (200 nM), Compound 20 (100 nM), or combinations for 24 hours. MAPK and 
PI3K signaling effects were determined by immunoblotting for pMEK (S217/221), pERK (pTpY185/187), and pAKT (S473). 
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for MET and GAB1 induction. Both lines exhibited clear 
increases in MET and GAB1 following vemurafenib and 
PD0325901 treatment (Figure 4D).
Induction of MET following vemurafenib 
treatment may serve as a predictive biomarker 
for identifying patients best suited for MET 
inhibitor combination therapy
Profiling BRAFV600E mutant melanoma cell lines 
identified considerable diversity in the degree of HGF 
rescue from vemurafenib (Figure 1C). Given this spectrum 
of response, we tested whether MET and GAB1 induction 
following vemurafenib treatment would predict for the 
degree of HGF rescue. We selected a subset of cell lines 
spanning a range of HGF rescue (Supplementary Table 2) 
and quantitatively measured total and phosphorylated MET 
and GAB1 in each following vehicle, vemurafenib, or 
vemurafenib + HGF treatment. As with previous signaling 
results (Figure 4D), clear induction of total MET and GAB1 
was observed in several cell lines following vemurafenib 
treatment (Figure 5A). Although elevated upon 
Figure 4: MAPK pathway inhibition mediates robust induction of MET and GAB1 levels, priming BRAFV600E mutant 
melanoma cells for HGF-mediated rescue. (A) Immunoblot analysis of indicated signaling proteins in BRAFV600E mutant G361 cells 
treated with vehicle, HGF (100 ng/mL), vemurafenib (2 μM), PD0325901 (200 nM), Compound 20 (100 nM), or specified combinations 
for 24 hours. (B) RT-PCR analysis of MET and GAB1 RNA levels in G361 cells following a time course vehicle or vemurafenib (2 μM) 
treatment. Bars represent SD across replicates (n = 4). (C) RT-PCR analysis of RTK and adaptor protein RNA levels in G361 cells following 
24-hour vehicle or vemurafenib (2 μM) treatment. Bars represent SD across replicates (n = 3). (D) Immunoblot analysis of MET and GAB1 
levels in BRAFV600E mutant melanoma cell lines rescued from the effects of BRAF inhibition by HGF. Cells were treated as in 4A.
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vemurafenib treatment, GAB1 levels were not predictive of 
HGF rescue under any treatment conditions tested (Figure 
5A). In contrast, MET levels following vemurafenib 
treatment demonstrated an enhanced association with 
HGF rescue strength. Here, the four cell lines with highest 
MET expression (G361, COLO679, SK-MEL-4, and SK-
MEL-24) also exhibited strongest HGF rescue. Similarly, 
pMET and pGAB1 levels following vemurafenib and 
HGF cotreatment were also predictive (Supplementary 
Figure 6), displaying similar patterns to those for total 
MET following vemurafenib treatment alone. The most 
compelling association was observed when the HGF 
rescue strength was compared with the fold increase in 
MET following vemurafenib treatment (R2 = 0.92, p-value 
= 0.003; Figure 5B), suggesting that total MET induction 
may serve as a predictive biomarker for identifying patients 
most likely to benefit from combined therapy with MET 
and MAPK pathway inhibitors.
Local/tumor HGF expression is required to 
convey resistance to BRAF inhibition in a 
BRAFV600E mutant melanoma xenograft model 
Previous reports have identified associations 
between tumor and plasma HGF expression and clinical 
response to vemurafenib [13, 14]. To investigate whether 
circulating HGF versus HGF present in the tumor 
microenvironment could mediate resistance to BRAF 
inhibition, G361 xenografts were used to generate 
models of systemic and local/tumor HGF expression 
(Supplementary Figure 7). To model systemic HGF 
expression, mice bearing G361 xenografts were treated 
with recombinant AAV containing an expression cassette 
for either human HGF (AAV-HGF) or GFP (AAV-GFP) 
as control. AAV-HGF treatment resulted in transduction 
of the liver and subsequent systemic expression of HGF. 
Mice were then treated with the BRAF inhibitor C-1 (10 
mg/kg, QD, by mouth [PO]) or vehicle and tumor growth 
was monitored to characterize HGF-mediated rescue. C-1 
was used in place of vemurafenib for this experiment 
as prior work had established a well characterized 
relationship between C-1 dose, exposure and target 
coverage in tumor xenograft models [35]. Systemic HGF 
expression driven via AAV-HGF at two different viral 
titers failed to rescue G361 xenografts from the growth 
inhibitory effects of BRAF inhibition following treatment 
with C-1 (Figure 6A, Supplementary Figure 8). 
To model local/tumor HGF expression, mice 
bearing Tet-HGF-G361 xenografts, with or without 
doxycycline in the drinking water, were treated with C-1 
or vehicle. Local/tumor HGF expression conveyed a 
significant rescue of C-1 driven tumor growth inhibition 
(P < 0.001; Figure 6B), suggesting local HGF expression 
may be required to mediate BRAF inhibitor resistance. 
Comparison of plasma and tumor HGF levels from the 
systemic and local/tumor HGF models revealed the 
highest plasma HGF levels in the high-dose AAV-HGF 
animals, whereas the highest tumor HGF levels were 
found in the Tet-HGF model (Supplementary Figure 9).
Our in vitro studies would predict that combined 
BRAF + MET inhibition should reverse the HGF-
mediated rescue of the BRAF inhibitor C-1 observed 
in the Tet-HGF-G361 xenograft study. Furthermore, 
analysis of the in-vitro studies would indicate that 
complete suppression of downstream MET signaling 
would be necessary to reverse HGF-mediated resistance 
to C-1. To achieve complete inhibition of MET signaling 
in-vivo, the MET kinase inhibitor AMG 337 was dosed 
at 20 mg/kg BID which is predicted to achieve plasma 
concentrations sufficient for > 90% inhibition of MET for 
24 hrs [27]. Combined treatment of the BRAF inhibitor 
C-1 (10 mg/kg, QD, PO) and AMG 337 (20 mg/kg, 
BID, PO) completely attenuated the HGF-mediated 
rescue of C-1 in Tet-HGF-G361 xenografts (Figure 6C). 
Subsequent pharmacodynamic analysis of downstream 
signaling pathways demonstrated HGF-dependent rescue 
of pERK upon the addition of doxycycline to the drinking 
water of C-1–treated mice (Figure 6D, Supplementary 
Figure 10). The increase in ERK phosphorylation was 
attenuated upon AMG 337 addition to C-1 treatment. As 
observed with BRAF inhibition in vitro, clear induction 
of total MET and GAB1 was observed following C-1 
treatment. Additionally, HGF-mediated increases in 
the phosphorylation of these two proteins were more 
pronounced following cotreatment with C-1 and 
doxycycline compared with doxycycline alone. These 
results suggest that repression of ERK-mediated negative 
feedback loops following BRAF inhibitor treatment 
primes total MET and GAB1 for HGF rescue, activating 
downstream signaling pathways and promoting tumor 
growth (Supplementary Figure 11). 
DISCUSSION
Resistance remains a significant limiting factor in 
achieving robust and durable clinical responses to targeted 
cancer therapy. More specifically, resistance to small-
molecule BRAF and MEK kinase inhibitors has been 
well-documented as limiting the efficacy of these agents 
in BRAFV600E mutant melanoma. Resistance is attributed 
to multiple mechanisms, including growth factor–
mediated activation of RTKs [13, 14]. In this study, we 
highlight the ability of HGF to rescue BRAFV600E mutant 
melanoma cell lines from the effects of BRAF and/or 
MEK inhibition, observing evidence of HGF rescue in the 
majority of profiled cell lines. Furthermore, we extended 
this observation to NRAS mutant melanoma. Here HGF 
rescued four of six NRAS mutant melanoma cell lines 
from MEK inhibition. 
Subsequent mechanistic studies revealed robust and 
rapid increases in MET and GAB1 transcript and protein 
levels following treatment with MAPK pathway inhibitors. 
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This finding was consistent with studies documenting 
elevated MET transcript levels in biopsies from tumors 
resistant to BRAF/MEK inhibitors [12]. Furthermore, 
cotreatment with HGF and a BRAF or MEK inhibitor 
increased MET and GAB1 phosphorylation beyond that 
observed with HGF alone. Downstream increases in ERK 
and AKT phosphorylation were also observed, suggesting 
that changes in total MET and GAB1 prime BRAF mutant 
melanoma cells for HGF-mediated rescue via downstream 
activation of the PI3K and MAPK signaling pathways 
(Supplementary Figure 11).
Detection of HGF-mediated resistance within 
the first few hours of inhibitor treatment indicated that 
the underlying resistance mechanism was dynamic and 
adaptive in nature and inherently different from the well-
documented acquired resistance mechanisms typically 
Figure 5: Fold increase in MET following BRAFi treatment predicts for strength of HGF rescue in BRAFV600E mutant 
melanoma cells. (A) Seven BRAFV600E mutant melanoma cell lines exhibiting varying degrees of HGF-mediated rescue (rank order left 
to right based on strength of HGF rescue) were treated with vehicle, vemurafenib (2 μM), HGF (100 ng/mL), or vemurafenib + HGF for 
24 hours. MET and GAB1 protein levels were measured using MSD assays. R2 values derived from linear regression analysis of MET or 
GAB1 values and fold HGF rescue for individual cell lines. (B) Correlation between fold HGF rescue and fold change in MET following 
vemurafenib treatment. M14 was omitted from analysis because MET levels fell below fell below the limit of detection.
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observed following extended drug treatment (weeks 
to months) [36]. Adaptive mechanisms are thought 
to represent the first step in a multistep process that 
culminates in therapeutic resistance. By providing the 
tumor cell with an immediate survival benefit, adaptive 
mechanisms allow cells to persist over time until a more 
robust and stable resistance mechanism presents, such as 
the acquisition of a drug-resistant genetic alteration [37]. 
Targeting the initial adaptive mechanism that promotes 
the evolution and persistence of drug tolerant cells may 
prevent the emergence of more stable acquired resistance 
and subsequently increase the duration and magnitude 
Figure 6: Elevated local/tumor HGF expression is required for resistance to BRAF inhibition in vivo. (A) Athymic nude 
mice bearing BRAFV600E mutant melanoma G361 tumor xenografts were treated intravenously with recombinant AAV vector containing 
human HGF (AAV-HGF) or GFP (AAV-GFP; 1 × 1012 viral particles/mouse). Three days post-administration, mice were treated with C-1 
(10 mg/kg QD) or vehicle. Tumor volumes were recorded twice weekly (mean ± SEM). (B) Athymic nude mice bearing Tet-HGF-G361 
tumor xenografts were administered doxycycline (0.1 mg/mL) to induce HGF expression. C-1 treatment was initiated the next day (10 mg/
kg QD). Tumor volume was monitored as in 6A. **P < 0.001 (BRAFi + HGF versus BRAFi – HGF). (C)| Tet-HGF-G361 tumor xenograft 
studies were conducted as in 6B. Mice were treated with vehicle, C-1 (10 mg/kg QD), AMG 337 (20 mg/kg BID), or C-1 and AMG 337 
in combination. ***P < 0.0001 (BRAFi + HGF versus BRAFi + HGF + METi or BRAFi – HGF). (D) Immunoblot analysis of signaling 
proteins from pharmacodynamic study of Tet-HGF-G361 tumor xenograft samples collected 6 hours after final drug treatment.
Oncotarget17805www.impactjournals.com/oncotarget
of therapeutic response. The unique role of HGF/MET 
signaling in conferring resistance to MAPK pathway 
inhibitors in BRAF and NRAS mutant melanoma 
suggests that combination therapy with small-molecule 
MET inhibitors may provide additional benefit beyond 
BRAF and MEK inhibitors alone. To test this, BRAFV600E 
mutant melanoma cell lines, rescued from the effects of 
BRAF or MEK inhibitors by HGF, were cotreated with a 
selective MET inhibitor. Clear attenuation of HGF rescue 
was observed, returning cells to a growth-arrested state 
when combined with a BRAF inhibitor and inducing cell 
death when combined with a MEK inhibitor. Subsequent 
analysis of underlying changes in pathway signaling 
revealed a reversal of the HGF-mediated rescue of PI3K 
and MAPK pathway signaling upon MET inhibition. We 
also determined that the strongest measure for predicting 
strength of HGF rescue in the BRAF mutant melanoma 
cell lines was the fold increase in MET levels following 
BRAF inhibitor treatment, suggesting that the induction of 
total MET may serve as a predictive biomarker to ascertain 
which patients with BRAFV600E mutant melanoma are most 
likely to exhibit adaptive resistance and benefit from MET 
inhibitor combination therapy. Initial reports documenting 
HGF-mediated resistance to BRAF inhibition in BRAF 
mutant melanoma identified correlations between HGF 
expression levels and patient response to BRAF and/or 
MEK inhibitor therapy. Using immunohistochemistry 
analysis of melanoma biopsies, an improved response to 
BRAF and/or MEK inhibitor therapy was found in patients 
with no detectable stromal HGF expression, as compared 
with those expressing HGF [13]. Alternatively, significant 
improvements in PFS and OS were found in patients 
with low plasma HGF levels [14]. To further investigate 
whether circulating HGF versus HGF present in the tumor 
microenvironment could mediate resistance to BRAF 
inhibition, we modeled systemic and local/tumor HGF 
expression systems in mice. We showed that systemic 
expression of HGF via AAV-HGF treatment failed to 
promote resistance to BRAF inhibition in G361 tumor 
xenografts, whereas local/tumor doxycycline–induced 
expression of HGF was capable of conferring resistance. 
These results suggest that HGF expression in the local/
tumor microenvironment may be required to successfully 
promote resistance to BRAF inhibition. 
Furthermore, treatment with AMG 337 (a selective 
MET inhibitor) completely attenuated HGF-mediated 
rescue. However, the reversal of HGF-mediated resistance 
to BRAF inhibition required the administration of AMG 337 
at a dose and schedule that would provide greater than 90% 
target coverage for 24hrs. This observation has potential 
translational significance, suggesting that circumvention of 
HGF mediated resistance to therapies targeting the MAPK 
pathway will require treatment with therapeutics capable of 
achieving complete inhibition of MET signaling. 
These findings demonstrate the role of HGF/
MET signaling in mediating resistance to BRAF and 
MEK inhibitors in BRAF and NRAS mutant melanoma. 
Monitoring changes in total MET and tumor HGF levels 
may have clinical utility for identifying patients most 
likely to benefit from combination therapy with inhibitors 
targeting the MAPK pathway and HGF/MET signaling.
MATERIAS AND METHODS
Cell lines and reagents
BRAF and NRAS mutant melanoma cell lines were 
obtained from various sources (Supplementary Methods). 
The tetracycline (Tet)-HGF-G361 cell line was generated 
as described (Supplementary Methods). Cell lines were 
maintained in vendor- or investigator-recommended 
media. Vemurafenib was purchased from Jubilant Life 
Sciences; the BRAF inhibitor C-1 [35, 38], dabrafenib, 
trametinib, the MET inhibitors AMG 337 and Compound 
20 (an AMG 337 analog), the PI3K inhibitor AMG 
511, and the MEK inhibitor PD0325901 were supplied 
by Amgen Inc. Antibodies against pMEK (S217/221), 
pAKT (S473), pMET (Y1234/1235), pGAB1 (Y627), 
MET, GRB2, SOS1, ERBB3, EGFR, IGF1R, FGFR1, 
IRS1, and PDGFRB were obtained from Cell Signaling 
Technology. Antibodies against pERK (T185/Y187; Life 
Technologies), GAB1 (Millipore), and beta-actin (Abcam) 
were also obtained.
Flow cytometry
Cell surface expression of MET was measured by 
flow cytometry as described in Supplementary Methods.
Animals
Female 4-6-week-old athymic nude mice 
(Charles River Laboratories) were housed according 
to all Association for Assessment and Accreditation of 
Laboratory Animal Care specifications. Experimental 
procedures were performed in accordance with 
Institutional Animal Care and Use Committee and US 
Department of Agriculture regulations.
Adeno-associated virus protein expression 
constructs
Recombinant adeno-associated virus (AAV) vectors 
containing expression cassettes for human HGF (AAV-
HGF) or green fluorescent protein (AAV-GFP) were 
produced and purified as previously described [39]. 
Live content imaging analysis and cell viability 
assay
Cells were seeded in 96-well plates at optimal 
density. Following overnight incubation, cells were 
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treated with compounds and/or growth factors at specified 
concentrations. Plates were imaged at 20× magnification 
every 3 hours for 5 to 8 days using an IncuCyte Live-
Cell Imaging System (Essen BioSciences) to monitor 
confluency changes over time. After imaging, cell viability 
was assessed using CellTiter-Glo® Luminescent Cell 
Viability Assay kits (Promega). 
Cell cycle analysis
Cells were seeded in six-well plates. After overnight 
incubation, cells were treated with compounds and/or 
growth factors for 48 hours. Bromodeoxyuridine (BrdU) 
labeling reagent was added for the final 2 hours. Cells 
were harvested, fixed in 90% methanol at –20°C, then 
treated with 2N HCl and 0.5% Triton X-100, and stained 
with anti-BrdU Alexa-647 and propidium iodide. Finally, 
cells were RNase-treated and analyzed via an LSRII flow 
cytometer (BD Biosciences), counting 20,000 events/
treatment condition.
Immunoblot analysis
Treated cells and xenograft tumors were lysed 
in radioimmunoprecipitation assay (RIPA) lysis buffer 
containing phosphatase and protease inhibitors. Lysates 
were cleared by centrifugation and concentrations were 
determined by Bio-Rad protein assay. Lysates were 
resolved using NuPAGE® gels (Life Technologies); 
membranes were blotted using total or phospho-specific 
antibodies (Supplementary Methods). 
Electro-chemiluminescence immuno assay
Lysates were prepared as described for immunoblot 
analysis and protein levels profiled using Meso Scale 
Discovery (MSD) 96-well singleplex assays. The standard 
manufacturer protocol was used for each commercially 
produced assay (total and pMET [Y1349], pERK1/2 
[T185/Y187], and pAKT [S473]). Custom GAB1 printed 
plates were developed using a total GAB1 capture antibody 
(Santa Cruz Biotechnology). Primary detection antibodies 
(2 μg/mL) were used for total GAB1 (Bethyl Laboratories) 
and p-GAB1 (Y627; Cell Signaling Technology); a 
commercial MSD SULFO-TAG labeled goat-anti-rabbit 
secondary detection antibody (2 μg/mL) was used. The 
standard manufacturer-recommended MSD protocol was 
used to detect total GAB1; the protocol was modified for 
phospho-GAB1 to include overnight incubation at 4°C and 
a 2-hour room temperature incubation with Y627 antibody. 
See Supplementary Methods for additional details.
Quantitative real-time polymerase chain reaction
Cellular RNA was extracted using QIAshredder 
and RNeasy Mini kits (Qiagen). Transcript levels were 
assayed using the TaqMan® One-Step RT-PCR Master 
Mix Reagents Kit and TaqMan® Gene Expression 
Assays (ThermoFisher Scientific). Quantitative real-time 
polymerase chain reaction (qRT-PCR) reactions were run 
as three or four technical replicates and assayed using 
the Prism® 7900HT (Applied Biosystems), applying the 
relative quantification (ΔΔCt) method. Data were analyzed 
with SDS2.3, RQ Manager v1.2, and Data Assist v3.01 
software (Applied Biosystems), using glyceraldehyde 
3-phosphase dehydrogenase as the endogenous control. 
Growth factor rescue experiments
BRAF and NRAS mutant melanoma cell lines 
were treated with vemurafenib, dabrafenib, trametinib, 
or PD0325901 and HGF or specified growth factors. 
Cells were incubated for 72 hours; viability was assessed 
using CellTiter-Glo Luminescent Cell Viability Assay 
kits. Luminescence was measured by EnVision® plate 
reader (PerkinElmer). Rescue magnitude was reported as 
percentage difference in raw luminescence (drug treatment 
+ indicated growth factor versus drug treatment alone).
Xenograft studies
In the systemic model, mice were injected 
subcutaneously with 5 × 106 G361 cells. When the tumor 
volume was approximately 200 mm3, mice were randomly 
assigned to receive intravenous injections of AAV-HGF or 
AAV-GFP (n = 10 each; 1–5 × 1012 viral particles/mouse 
in 0.2 mL phosphate-buffered saline [PBS], single dose). 
Inhibitor treatment began 3 days after AAV administration. 
In the tumor/autocrine model, mice received 5 × 106 
G361cells engineered to express HGF under the control 
of a tetracycline-inducible promoter (Tet-HGF). Drinking 
water containing 0.1 mg/mL doxycycline was administered 
at randomization to induce tumor HGF expression, and 
inhibitor treatment began 1 day later. Mice were treated 
orally with vehicle, C-1 (10 mg/kg once daily [QD]), AMG 
337 (20 mg/kg twice daily [BID]), or C-1 and AMG 337 
in combination. Tumor volumes and body weights were 
measured twice weekly. A pharmacodynamic study was 
performed on mice harboring Tet-HGF-G361 xenografts. 
Mice received 24 hours of dosing; tumors were harvested 6 
hours after the 24-hour dose (second dose of C-1, third dose 
of AMG 337).
Determination of plasma and tumor hepatocyte 
growth factor levels
Human HGF levels were measured in plasma and 
tumor lysates from mice bearing G361 xenografts using the 
MSD 96-well singleplex HGF assay. To quantify plasma 
HGF levels, blood was collected via cardiac puncture into 
ethylenediaminetetraacetic acid-coated tubes; plasma was 
separated by centrifugation and processed in the HGF 
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assay according to the manufacturer’s protocol (25 µL 
plasma/well). 50 µg lysate/well were used to measure 
tumor HGF levels.
Statistical analysis
For in vitro analyses, error bars represent the 
standard deviation (SD) from replicate data points; 
statistical significance was established using a two-tailed 
unpaired t test assuming unequal variance. Statistical 
significance from xenograft studies was determined by 
repeated measures analysis of variance.
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